Scientific Rigor. Entrepreneurial Agility.
Apogee is an early-stage drug discovery company with a fully equipped research facility and wet laboratory in Greater Vancouver, British Columbia, Canada. Apogee’s drug discovery concentrates on a spectrum of the most challenging diseases within autoimmune and inflammatory diseases, respiratory conditions, endometriosis, and the endocannabinoid system. By zeroing in on these immune-driven domains, Apogee is focused on building and acquiring a pipeline of novel therapeutics aimed at delivering solutions for diseases with high unmet medical needs.
Apogee was founded in 2022 to acquire nearly all the assets of a Vancouver-based biotechnology company that started in 2014 and was focused primarily on the endocannabinoid system (ECS). Apogee acquired the intellectual property (including patents and patents pending) and wet laboratory of this company and hired the best scientists to continue work within ECS and other areas.
Apogee is guided by a highly experienced leadership team with decades of collective expertise spanning pharmaceutical research and development, corporate strategy, and operational management. Apogee’s executive team is composed of accomplished professionals from leading global pharmaceutical and biotechnology companies, bringing deep domain knowledge in drug discovery, immunology, ECS, and translational science. Collectively, they have an extensive track record of successfully advancing therapeutic candidates from early discovery through clinical development, including IND-enabling studies, and regulatory submissions.
Apogee fosters a team culture grounded in scientific excellence, operational agility, and an unwavering commitment to translational impact. This environment enables it to rapidly and rigorously move scientific insights from bench to bedside, accelerating the development of innovative therapies for patients with high unmet medical need.
Apogee is owned by a healthcare-focused investment firm, benefiting from substantial financial resources, strategic guidance, and a long-term commitment tailored to the demands of biomedical innovation. This relationship enables Apogee to advance high-impact scientific programs with both agility and rigor, supporting investments in platform development, early-stage research, and team expansion. While Apogee is in the early stages of building and broadening its existing intellectual property portfolio, the strength and stability of its backing provides a solid foundation for sustained growth, empowering it to pursue ambitious research objectives and expand its capabilities with confidence.